Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

A multicentric, randomized, controlled phase III study of centhaquine (Lyfaquin®) as a resuscitative agent in hypovolemic shock patients

View ORCID ProfileAnil Gulati, Rajat Choudhuri, Ajay Gupta, Saurabh Singh, S. K. Noushad Ali, Gursaran Kaur Sidhu, Parvez David Haque, Prashant Rahate, Aditya R Bothra, G P Singh, Sanjeev Maheshwari, Deepak Jeswani, Sameer Haveri, Apurva Agarwal, Nilesh Radheshyam Agrawal
doi: https://doi.org/10.1101/2020.07.30.20068114
Anil Gulati
1Pharmazz, Inc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anil Gulati
  • For correspondence: anil.gulati@pharmazz.com
Rajat Choudhuri
2Institute of Postgraduate Medical Education & Research/SSKM Hospital, Kolkata, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ajay Gupta
3Chiranjeev Medical Ctr, Jhansi, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Saurabh Singh
4Inst of Medical Sciences, Banaras Hindu Univ, Varanasi, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. K. Noushad Ali
5ACSR Government Medical Coll & Hosp, Nellore, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gursaran Kaur Sidhu
6Sidhu Hosp Pvt. Ltd., Ludhiana, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Parvez David Haque
7Christian Medical Coll & Hosp, Ludhiana, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Prashant Rahate
8Seven Star Hosp, Nagpur, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aditya R Bothra
9Rahate Surgical Hosp & ICU, Nagpur, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G P Singh
10King Georges Medical Univ, Lucknow, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sanjeev Maheshwari
11Jawahar Lal Nehru Medical Coll & Attached Hosp, Ajmer, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deepak Jeswani
12Criticare Hosp & Res Inst, Nagpur, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sameer Haveri
13KLEs Dr. Prabhakar Kore Hosp & Medical Res Ctr, Belgaum, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Apurva Agarwal
14GSVM Medical Coll, Kanpur, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nilesh Radheshyam Agrawal
15New Era Hosp & Res Inst, Nagpur, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Centhaquine is a novel, first-in-class resuscitative agent for the treatment of hypovolemic shock. Efficacy of centhaquine for the treatment of hypovolemic shock as an adjuvant to standard of care (SOC) was evaluated in a prospective, multi-center, randomized, double-blind, controlled phase III study. Key inclusion criteria were, systolic blood pressure (SBP) of ≤90 mm Hg, blood lactate levels of ≥2 mmol/L and patients receiving SOC in a hospital or ICU setting. Primary endpoints of the study were change in SBP, diastolic blood pressure (DBP), blood lactate levels and base deficit. Mortality through day 28 was the key secondary endpoint. A total of 197 patients were screened, of which 105 patients met eligibility criteria and were included in the study. Patients were randomized in a 2:1 ratio, 71 patients to centhaquine (0.01 mg/kg, IV infusion) group and 34 patients to control group. SOC was provided to both centhaquine and control groups. Demographics were similar in both groups, except patients in saline group were few years younger. Difference between the mean in control and centhaquine groups of hemoglobin level was 0.769 ± 0.590 (P=0.0984) and in hematocrit level was 2.419 ± 1.899 (P=0.1036) at the time of inclusion. Centhaquine substantially reduced 28-day all-cause mortality. In control group, mortality rate was 11.76% compared to 2.94% in centhaquine group (odds ratio: 4.4; 95% CI 0.9651 to 23.74 and P=0.037). At 24 hours of resuscitation, SBP of more than 110 mmHg was in 60.61% patients of control and 79.69% patients of centhaquine group (P=0.0222; OR=2.55); while DBP of more than 70 mmHg was in 51.52% patients of control and 76.56% patients of centhaquine group (P=0.0061; OR=3.075). The number of patients with blood lactate levels of 1.5 mmol/L or less were 46.88% in control group compared to 69.35% in centhaquine group (P=0.0168; OR=2.565). The number of patients with base-deficit of less than minus 2 were 43.75% in control group compared to 69.84% in centhaquine group (P=0.0069; OR=2.977). Shock index improved in centhaquine but not in control group in the first 6 hours of resuscitation. Centhaquine improved acute respiratory distress syndrome (ARDS) and multiple organ dysfunction score (MODS). No drug related adverse event was reported. Centhaquine (Lyfaquin®) is a highly efficacious resuscitative agent for the treatment of hypovolemic shock as an adjuvant to SOC.

Competing Interest Statement

Anil Gulati is a stockholder and employee of Pharmazz, Inc. All other authors have no competing interest to declare.

Clinical Trial

NCT04045327 (Clinical Trials Registry, India CTRI/2019/01/017196). The study protocol (PMZ-2010/CT-3.1/2018) was approved by the Drug Controller General of India (DCGI), Ministry of Health and Family Welfare, Government of India and Institutional Ethics Committee of all the 14 Institutions.

Funding Statement

The present study was funded by Pharmazz, Inc. Toxicological study of centhaquine in dog was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number R43HL137469.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Included additional data and improved discussion

Data Availability

The data are not publicly available due to restrictions that could compromise the privacy of research participants. The data that support the findings of this study are available from the corresponding author, upon reasonable request. The study protocol (PMZ-2010/CT-3.1/2018) was approved by the Drug Controller General of India (DCGI), Ministry of Health and Family Welfare, Government of India and Institutional Ethics Committee of all the 14 Institutions.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted November 05, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
A multicentric, randomized, controlled phase III study of centhaquine (Lyfaquin®) as a resuscitative agent in hypovolemic shock patients
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
A multicentric, randomized, controlled phase III study of centhaquine (Lyfaquin®) as a resuscitative agent in hypovolemic shock patients
Anil Gulati, Rajat Choudhuri, Ajay Gupta, Saurabh Singh, S. K. Noushad Ali, Gursaran Kaur Sidhu, Parvez David Haque, Prashant Rahate, Aditya R Bothra, G P Singh, Sanjeev Maheshwari, Deepak Jeswani, Sameer Haveri, Apurva Agarwal, Nilesh Radheshyam Agrawal
medRxiv 2020.07.30.20068114; doi: https://doi.org/10.1101/2020.07.30.20068114
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
A multicentric, randomized, controlled phase III study of centhaquine (Lyfaquin®) as a resuscitative agent in hypovolemic shock patients
Anil Gulati, Rajat Choudhuri, Ajay Gupta, Saurabh Singh, S. K. Noushad Ali, Gursaran Kaur Sidhu, Parvez David Haque, Prashant Rahate, Aditya R Bothra, G P Singh, Sanjeev Maheshwari, Deepak Jeswani, Sameer Haveri, Apurva Agarwal, Nilesh Radheshyam Agrawal
medRxiv 2020.07.30.20068114; doi: https://doi.org/10.1101/2020.07.30.20068114

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Intensive Care and Critical Care Medicine
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (557)
  • Anesthesia (135)
  • Cardiovascular Medicine (1769)
  • Dentistry and Oral Medicine (238)
  • Dermatology (173)
  • Emergency Medicine (316)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (662)
  • Epidemiology (10812)
  • Forensic Medicine (8)
  • Gastroenterology (594)
  • Genetic and Genomic Medicine (2960)
  • Geriatric Medicine (288)
  • Health Economics (534)
  • Health Informatics (1933)
  • Health Policy (836)
  • Health Systems and Quality Improvement (745)
  • Hematology (293)
  • HIV/AIDS (633)
  • Infectious Diseases (except HIV/AIDS) (12525)
  • Intensive Care and Critical Care Medicine (696)
  • Medical Education (300)
  • Medical Ethics (87)
  • Nephrology (324)
  • Neurology (2808)
  • Nursing (152)
  • Nutrition (433)
  • Obstetrics and Gynecology (559)
  • Occupational and Environmental Health (597)
  • Oncology (1473)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (257)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (381)
  • Pediatrics (868)
  • Pharmacology and Therapeutics (367)
  • Primary Care Research (338)
  • Psychiatry and Clinical Psychology (2646)
  • Public and Global Health (5383)
  • Radiology and Imaging (1016)
  • Rehabilitation Medicine and Physical Therapy (597)
  • Respiratory Medicine (727)
  • Rheumatology (330)
  • Sexual and Reproductive Health (290)
  • Sports Medicine (279)
  • Surgery (327)
  • Toxicology (48)
  • Transplantation (150)
  • Urology (126)